Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan

Table 1 Demographics and baseline characteristics

	Vildagliptin group(n = 55)	Sulfonylureagroup (n = 42)
Age (yr)	51.0 ± 8.8	50.9 ± 9.1
≥ 65 yr	4 (7.3)	4 (9.5)
Weight, kg	69.1 ± 10.9	67.4 ± 10.0
Height, cm	159.7 ± 8.1	158.4 ± 9.8
HbA1c, % (mmol/mol)	8.75 ± 1.27 (72.10 ± 13.90)	8.64 ± 1.57 (70.92 ± 17.14)
HbA1c < 7.0% (< 53.0 mmol/mol)	3 (5.5)	6 (14.3)
FPG, mg/dL	140.2 ± 42.0	162.1 ± 48.2
PPG, mg/dL	212.2 ± 52.2	220.6 ± 54.0
Patients receiving metformin, n (%)	38 (69.1)	30 (71.4)
Mean doses of sulfonylureas, mg/d
Glibenclamide (n = 7)	-	10
Gliclazide (n = 10)	-	106
Glimepiride (n = 23)	-	4.2
Glipizide (n = 2)	-	10

Data are shown as mean ± SD or n (%), unless otherwise stated. Vildagliptin group: Patients receiving vildagliptin ± metformin; Sulfonylurea group: Patients receiving sulfonylurea ± metformin; FPG: Fasting plasma glucose; PPG: Postprandial plasma glucose.

Table 2 Safety and tolerability of vildagliptin and sulfonylurea n (%)

Adverse events	Vildagliptin group(n = 55)	Sulfonylurea group(n = 42)
Number of patients with adverse event(s)	3 (5.5)	4 (9.5)
Palpitation	2 (3.6)	1 (2.4)
Gastrointestinal disturbances	2 (3.6)	0 (0.0)
Hypoglycemia	0 (0.0)	2 (4.8)
Headache	0 (0.0)	1 (2.4)
Nausea	0 (0.0)	1 (2.4)